Doak and Kenwood
Sinecatechins 15%; ointment.
External genital and perianal warts (Condylomata acuminata) in immunocompetent patients ≥18 years. Pharmacology: Veregen is a topical ointment that delivers sinecatechins, a partially purified fraction of the water extract of green tea leaves from Camellia sinensis (L.) O. Kuntze. Sinecatechins is a mixture of catechins and other components of green tea. Catechins comprise about 85%-95% of the drug substance while the other components (gallic acid, theobromine, and caffeine) make up about 2.5%. The remainder of the drug substance contains undefined botanical constituents derived from green tea leaves. The vehicle for Veregen is a water-free mixture that contains isopropyl myristate, white petrolatum, cera alba, propylene glycol palmitostearate, and oleyl alcohol.
The mechanism of action of sinecatechins is unknown. Antioxidant properties have been demonstrated in vitro, but the clinical significance of this finding is unknown.
The safety and efficacy of Veregen was evaluated in two randomized, double-blind, vehicle-controlled studies in immunocompetent patients. The median baseline number of warts was six (range 2-30). The primary efficacy outcome measure was the response rate, defined as the proportion of patients who had complete clinical (visual) clearance of all warts (both baseline and new ones) by week 16. Subjects applied the ointment three times daily for up to 16 weeks or until complete clearance. Data were examined both for patients in the U.S. only and for those in all countries in which testing occurred. For all countries, treatment with Veregen resulted in a complete clearance rate of 53.6%, compared with 35.3% for vehicle.
For patients in the U.S. alone, the response rates were 23.8% for Veregen and 0% for vehicle. When examined for efficacy by gender, 47.3% of males treated with Veregen had complete clearance compared with 60.4% of females, while 28.8% of males using vehicle had a complete clearance, compared with 43.8% of females using vehicle. The median time to clearance was 16 weeks in one study and 10 weeks in the other. In patients with complete clearance, the rates of recurrence of warts 12 weeks after completion of therapy were 6.8% for those who had used Veregen compared with 5.8% for those who had used vehicle.
≥18years: Wash hands. Apply ointment to each wart three times daily for up to 16 weeks. Do not cover treated area.
<18 years: not recommended.
Do not use on internal or mucous membrane warts or on broken skin. Caution with tampon insertion (avoid inadvertent internal application). Wash ointment off if severe reaction occurs. Avoid sexual contact with ointment on skin. Immunosuppressed. May stain fabrics. Avoid sun, UV light on treated area. Pregnancy (Cat. C). Nursing mothers.
Concomitant use of condoms or diaphragm: not recommended (ointment may weaken rubber).
Local reactions (e.g., erythema, erosion, edema, itching, burning), phimosis, inguinal lymphadenitis, urethral meatal stenosis, dysuria, rash, desquamation, bleeding, hypersensitivity, superinfection.
Ointment—15 g, 30 g
For more information, call 973.882.1505 or visit www.Veregenrx.com